2023 Fall Conference | C26 - Neurology Update 8: Neuromuscular Disease and Autonomic Disorders

Date Sunday 10/29/23

Time 09:30 AM - 11:00 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Robert M. Pascuzzi, MD, FAAN

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Attendees should become familiar with expanding options in the treatment of myasthenia gravis; enhance their understanding of management considerations for patients with motor neuron disease; and acquire clinical pearls in the diagnosis and treatment of myopathies, neuropathies, and disorders of the neuromuscular junction. Attendees should also learn how to develop a diagnostic approach to the patient with autonomic failure; understand the natural history and disease trajectory of patients with autonomic failure; and be able to develop a differential diagnosis of patients presenting with autonomic features.

CME Available 1.50 CME credits

Program Materials

Event Timeline
09:30 AM - 10:15 AM PDT	Speaker	Neuromuscular Robert M. Pascuzzi, MD, FAAN
10:15 AM - 11:00 AM PDT	Speaker	Autonomic Disorders Roy L. Freeman, MD

Faculty Disclosures
Robert M. Pascuzzi, MD, FAAN	Dr. Pascuzzi has nothing to disclose.
Roy L. Freeman, MD	Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenacy. Dr. Freeman has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurobo. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Freeman has stock in Neurobo. Dr. Freeman has stock in Cutaneous NeuroDiagnostics. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck.

��ɫ��

��ɫ��